U.S. Markets closed

Cumberland Pharmaceuticals Inc. (CPIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.06+0.09 (+1.29%)
At close: 4:00PM EDT
People also watch
CRMECORTCDXSALIMBIOD

Cumberland Pharmaceuticals Inc.

2525 West End Avenue
Suite 950
Nashville, TN 37203
United States
615-255-0068
http://www.cumberlandpharma.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees82

Key Executives

NameTitlePayExercisedAge
Mr. A. J. Kazimi MBAFounder, Chairman, Chief Exec. Officer and Pres700.45kN/A59
Mr. Michael P. BonnerChief Financial Officer and Sr. Director of Fin. & Accounting200.1kN/A40
Mr. Leo B. Pavliv R.Ph.Chief Devel. Officer and Exec. VP of Operations360.95kN/A56
Mr. James Lowrance HermanChief Compliance Officer and Sr. VP of National Accounts270kN/A62
Mr. Martin E. CearnalChief Commercial Officer, Exec. VP and Director345.1kN/A72
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. The company’s product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis; and Totect injection for emergency oncology intervention, which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc, Nordic Group B.V., and Cumberland Emerging Technologies. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.